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Abstract
Orofacial clefts are among the most common birth defects and result in an improper formation of the mouth or the roof of
the mouth. Monosomy of the distal aspect of human chromosome 6p has been recognized as causative in congenital
malformations affecting the brain and cranial skeleton including orofacial clefts. Among the genes located in this region is
PAK1IP1, which encodes a nucleolar factor involved in ribosomal stress response. Here, we report the identification of a
novel mouse line that carries a point mutation in the Pak1ip1 gene. Homozygous mutants show severe developmental
defects of the brain and craniofacial skeleton, including a median orofacial cleft. We recovered this line of mice in a forward
genetic screen and named the allele manta-ray (mray). Our findings prompted us to examine human cases of orofacial
clefting for mutations in the PAK1IP1 gene or association with the locus. No deleterious variants in the PAK1IP1 gene coding
region were recognized, however, we identified a borderline association effect for SNP rs494723 suggesting a possible role
for the PAK1IP1 gene in human orofacial clefting.
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Introduction
Among the most common birth defects are clefts of the lip and/
or palate (CL/P), which affect about one in 700 births worldwide
[1,2]. Orofacial defects can be syndromic, with a variety of other
clinical features, or isolated (approximately 70%) and can involve
major difficulties with food intake, speech, hearing and ensuing
psychological development. As a subset of orofacial clefts, median
clefts are extremely rare and originate from the failure of the
frontonasal processes to fuse along the midline during develop-
ment. Orofacial clefts have a complex and poorly understood
etiology with both genetic and environmental factors contributing.
Some progress in the identification of genes implicated in CL/P
disorders has occurred over the last decade, with a major
contribution for new candidate genes in recent years from
Genome Wide Association Studies (GWAS) [3–5]. Nevertheless,
variants in these genes (e.g. IRF6, MAFB, ARGHAP29, VAX1,
8q24) do not account for all cases with genetic etiology underlining
the need for identifying new genes contributing to the burden of
orofacial clefts and the molecular processes they regulate [2,6].
One chromosomal region of importance for orofacial clefts is
6p24 (orofacial cleft 1, OMIM 119530) with several studies
suggesting an associated locus. Chromosomal translocation
breaking points in patients with orofacial clefts have been finely
mapped to 6p24.3 [7,8]. TFAP2A lies within this region; mutations
in this gene, which encodes a transcription factor, cause branchio-
ocular-craniofacial syndrome, an autosomal dominant disorder
that includes CL/P [9]. In addition, TFAP2A regulates through a
specific binding site the expression of IRF6, causative in Van der
Woude syndrome, which can include CL/P. Interestingly, this
binding site contains a variant (rs642961) that disrupts TFAP2A
binding and is overtransmitted in clefting patients [10]. Additional
genes, distal to the translocation breaking points, include several
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important regulators of developmental processes such as BMP6
and several members of the FOX gene family, but none has been
with certainty associated with orofacial clefts. In addition, several
studies have shown linkage of CL/P syndromes to markers in 6p23
[11–14].
PAK1IP1 (Pak1 interacting protein 1), maps to 6p24.2 approx-
imately 203 kb centromeric from OFC1. The encoded protein is
also known as hPIP1 (human Pak1 Interacting Protein 1) or as the
yeast homolog Skb15 (Schizosaccharomyces pombe Shk1 kinase
binding protein 15) and was initially identified in two independent
yeast two-hybrid screens using yeast and human Pak1 (P21-
activated kinase) as bait respectively [15,16]. P21-activated kinases
(PAKs) are serine-threonine protein kinases that are positively
regulated by the small GTPases, Cdc42 and Rac1 [17,18]. In
vertebrates PAKs control diverse cellular processes, including gene
expression, cytoskeletal actin and tubulin assembly, neurite
outgrowth, cell cycle control, and apoptosis. Pak1ip1 is largely
comprised of WD40 repeats and was initially described as a
negative regulator of Pak1. Interestingly, more recent research has
shown that Pak1ip1 also localizes to the nucleolus where it is
involved in ribosome biogenesis, in light of which its interaction
with Pak1 and the cellular events it mediates through this function
appear secondary [19]. By facilitating ribosomal RNA processing,
Pak1ip1 plays a regulatory role in cell growth and proliferation
apparently through direct interaction with the tumor protein 53
(Tp53)-murine double minute 2 (Mdm2) loop upon cellular stress
[20]. Furthermore, by causing craniofacial anomalies if mutated,
Pak1ip1 joins a group of molecules causative in ribosomopathies
associated with craniofacial defects. They include for instance
TCOF1 (Treacher-Collins-Franceschetti syndrome 1) and ribo-
somal proteins S19 and S24 (RPS19, RPS24) in Diamond-
Blackfan anemia [21,22].
Here, we demonstrate that Pak1ip1 is a factor required for
proper craniofacial morphogenesis presumably by its unique role
in ribosome biogenesis, further adding to our understanding of
craniofacial morphology and its underlying molecular regulation.
Results
manta-ray, a novel mouse line with orofacial clefting
In a forward genetic screen aimed at identifying mutations
affecting neural development in mice [23], we recovered a mutant
line with wide-ranging defects including median orofacial clefting.
The mutation displayed autosomal-recessive inheritance and we
named the line manta-ray (mray) due to the pathological morphology
resulting from the clefting of the maxillae and secondary palate of
the homozygous mutants (figure 1). At embryonic day (E)14.5 the
palatal shelves of homozygous mutants elevate but fail to meet and
fuse at the midline. Midline structures of the frontonasal skeleton,
such as the nasal septum are severely reduced. Brain defects
included a considerably smaller forebrain and hindbrain, which in
part can be attributed to smaller ventricles (figure 1 and data not
shown) but a relatively enlarged midbrain. In addition, most
affected mutants are overall smaller at all stages, appear
developmentally delayed, and a subcutaneous edema, possibly
due to a heart and/or lymphatic defect, covers almost the entirety
of the body (figure 2). The hypoplasia of craniofacial structures
affects also the developing musculature as a comparison between
the masseter muscles of wild-type and homozygous mutants
demonstrates (figure 2). While mray homozygous mutants die as
embryos, usually at around 14 days of gestation, heterozygotes
appear phenotypically unaffected, are fertile, and have a normal
lifespan.
Employing microsatellite-based positional mapping and scoring
more than 1500 meioses from separate crosses (heterozygote
carriers, affected, and non-affected embryos), we confined the mray
mutation to a 3.75 Mb-interval on chromosome 13 between
markers D13Mit177 and D13Mit63 containing 20 protein-coding
genes (list in figure 3). We sequenced all coding sequences in these
genes and identified only one base pair substitution (C to T
transition) in the Pak1ip1 gene not present in the parental strains
(C57BL/6J and FVB/NJ). The mutation leads to the substitution
Figure 1. Homozygous mray mutants show severe craniofacial
malformations starting early in development. A, B, Fluorescent
images of a wild-type embryo compared to a homozygous mray
littermate at E12.5. The dashed lines indicate the relative decrease in
the size of the forebrain (red) but increase in the size of the midbrain in
the mutant (green) respectively. In C and D frontal views of the head
photographed under fluorescent lighting illustrate the median cleft of
affected mutants. E, F, Nissl-stained coronal sections of the oral cavity
of 14.5 day old embryos show that the palatal shelves in homozygous
mray mutants fail to sufficiently grow out and eventually fuse. FB:
forebrain, MB: midbrain, OC: oral cavity, PS: palatal shelf, TB: tooth bud,
To: tongue. Scale bars in A–D are 1 mm and in E and F 250 mm.
doi:10.1371/journal.pone.0069333.g001
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of a single amino acid residue from a histidine to a tyrosine in an
entirely conserved position of the protein as sequence alignments
of all known orthologs show (figure 3 and data not shown).
Consequently, the mray allele presents the first mutant Pak1ip1
allele described in mice, rendering this mouse line a very valuable
model to study the effects of Pak1ip1 inactivation in vivo.
Expression of Pak1ip1 and midfacial specification in
affected manta-ray mutants
To better assess the role of Pak1ip1 during development and
identify clues as to how its inactivation may result in
developmental defects, we observe in affected mray embryos, we
examined its expression during various embryonic stages. We
conducted RNA in situ hybridization analysis on whole-mount
embryos and sections of embryonic tissue. Our results show that
Pakip1 is widely expressed in the embryo, consistent with its role
in ribosome biogenesis on which every cell depends. Specifically,
Pak1ip1 is expressed throughout the embryo with somewhat
higher levels of expression in forebrain, facial primordia, limb
buds, and liver (figure 4). Interestingly, the higher expression
levels of Pak1ip1 in forebrain, facial structures, and liver,
correspond to some of the most severely affected areas of the
mray/mray embryos. These findings may point towards a
particularly important role for Pak1ip1 expression levels in the
histogenesis of certain organs.
Pak1ip1 has been implicated in the regulation of both
cytoskeletal regulation through the inhibition of the serine/
threonine kinase Pak1 [15,16] and ribosome biogenesis [19,20].
The multiple and complex cellular functions Pak1ip1 may
mediate, presents a challenge in understanding the molecular
and cellular mechanisms underlying the median cleft in the mray/
mray animals. To explain the midline cleft in homozygous mutants,
we first considered local effects such as a specific deficit in
patterning and specification of midfacial structures during
development. During midgestational stages (E8.5 – E10) the
frontonasal process, which will give rise to midfacial structures, is
characterized by the expression of several factors that exert
proliferative activity and are critical for proper outgrowth. Of
particular relevance in this context are members of the fibroblast
growth factor (Fgf) family and sonic hedgehog (Shh) [24–26].
Interestingly, Pak1 has been shown in a recent study to participate
in the Fgf signaling pathway, which also interacts with the Shh
pathway [27]. To examine possible changes in the expression of
genes required to form the medial face we carried out whole-
mount RNA in situ hybridization for Fgf8, Fgf17, and Shh on wild-
type, heterozygotes, and mutants. Analyzing stages E9.0 to E11.5
(figure 5 and data not shown), we detected only mild changes in
expression levels and distribution of these molecular markers but
largely intact expression domains. Specifically, at E9.5 the
midfacial expression domains of Fgf8 and Fgf17 largely overlapped
with the frontonasal prominence and formed bilateral stripes
around the midline, irrespective of genotype. Some low-level
variation in the size of the expression domains, we attributed to
size differences between wild-type and mray/mray embryos. Shh
Figure 2. Midline clefting and reduced growth inmray/mraymutants. Frontal and side-views of an E15 wild-type embryo (A, B) compared to
a homozygous mray littermate (E, F). The mutant is overall smaller and in the frontal view in E the median cleft (arrowheads) and large-scale edema
(asterisks) covering almost the entirety of the body except for head and limbs can be appreciated. The dashed lines in the lateral views in B and F
indicate the approximate positions of the sections in C and G respectively. C, G Hematoxylin-eosin-stained horizontal sections through the head and
upper body show morphological changes in the homozygous mray mutant. The maxillary processes (MP) fail to fuse at the midline (arrowhead in G)
resulting in a median cleft. Midline structures such as the nasal septum are absent and the back is covered by a skin edema (asterisks). Horizontal
sections in D and H illustrate the severe hypoplasia of the masseter muscle in the mutant. C3 cervical vertebra 3, FB: forebrain, Hu: humerus, Ma:
masseter muscle, MC: Meckel’s cartilage, MB: midbrain, OC: oral cavity, Pa: secondary palate, SC: spinal cord, Sca: scapula, SG: salivary gland, TB: tooth
bud, To: tongue. Scale bars are 1 mm in A and C and 200 mm in D.
doi:10.1371/journal.pone.0069333.g002
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displayed a similar, but ventrally shifted, expression pattern, which
was slightly diminished in the mutant compared to the wild-type
but correlated well with the overall smaller size of the mutant
embryos. Overall, our results suggested, if any, a minor
contribution of midfacial molecular patterning to the manifesta-
tion of midline clefting in homozygous mray mutants.
Figure 3. Positional mapping and identification of the causative mutation in the Pak1ip1 gene. A, Ensembl-generated (version 67.37,
NCBIm37) image of the genomic interval between markers D13Mit177 and D13Mit 63 the manta-ray (mray) mutation was mapped to. The coding
sequences of all Ensembl/Havana genes shown in this diagram were sequenced but only one mutation was found, in the Pak1ip1 gene (boxed). The
sequenced genes list from proximal to distal as follows: Slc35b3, Ofcc1, Gm9979, Tfap2a, Gcnt2, A730081D07Rik, Pak1ip1, Tmem14c, Mak, Gcm2,
Sycp2l, Elovl2, BC024659, GM17364, Nedd9, Tmem170b, Gm5082, 9530008L14Rik, Hivep1, Edn1. Angled brackets indicate gene directionality. B,
Sequence chromatograms of wild-type and mray PCR amplicons showing the position of the mutation (C to T) in the trace. C, Schematic structure of
the Pak1ip1 protein with WD 40 repeats indicated as red boxes and the first residue of every WD 40 repeat indicated below. The mutation leads to
the substitution of a histidine residue by a tyrosine residue in the first position of the third WD 40 repeat. This position of the protein is entirely
conserved as shown by the sequence alignment of six species below.
doi:10.1371/journal.pone.0069333.g003
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Subcellular localization of Pak1ip1 and Tp53 regulation
The phenotype of homozygous mray carriers has a complex and
pleiotropic nature, which affects many organs and tissues without
interfering with their initial development. In previous studies,
Pak1ip1 has been shown to localize to the nucleolus and
participate in ribosome biogenesis [19,20]. Indeed, the overall
reduction in size of homozygous mray mutants could be well
explained by a general deficit in protein biosynthesis resulting in a
prolonged cell cycle or even cell cycle arrest and reduced growth.
To obtain further insight into the function of Pak1ip1 and its
possible deregulation in the mray mutant, we examined its
Figure 4. Developmental expression of the Pak1ip1 gene. Expression analysis of Pak1ip1 at midgestational time points ranging from E9.5 to
E13.5 uncovers wide-ranging expression of the mRNA. Whole-mount RNA in situ hybridization on E9.5 (A) and E10.5 (B) embryos reveals that Pak1ip1
is widely expressed throughout the embryo. Slightly higher expression levels can be seen in the brain, limbs, and facial primordia. Almost no
transcripts can be detected in the heart of either stage. In C RNA in situ hybridization with a radiolabelled (35S) Pak1ip1 probe on parasagittal section
of an E13.5 embryo shows low-level expression in most tissues but higher transcript levels in forebrain, facial mesenchyme and particularly liver. BA 1:
first branchial arch, FB: forebrain, FLB: forelimb bud, HB: hindbrain, He: heart, HLB: hindlimb bud, Li: liver, LNP: lateral nasal prominence, MB: midbrain,
Mx: maxillary process, SC: spinal cord. Scale bar in C is 1 mm.
doi:10.1371/journal.pone.0069333.g004
Figure 5. Midfacial specification in mray/mray embryos shows only mild changes compared to wild-type littermates. Whole-mount
RNA in situ hybridizations reveal expression domains of Fgf8 (A, B F, G), Fgf17 (C, H), and Shh (D, E, I, J) in wild-type and mutant embryos at stages
E9.0 to E10.5. Only mild changes in the midfacial expression domains of these genes can be seen in homozygous mray mutants, suggesting an overall
proper specification of the midface. The slightly smaller expression domains of all analyzed genes in the E9.0 and E9.5 mray/mray embryos correlate
well with overall smaller size of these embryos. Particularly, at E10.5 the overall smaller size and developmental delay of the mutant embryos
becomes apparent (G, J). In the mutant, considerably lower Shh expression along the ectodermal odontogenic line is probably due to general
developmental delay and marked by asterisks in J. BA1, 2: branchial arch1, 2, FNP: frontonasal prominence, LNP: lateral nasal process, ML: midline, MP:
mandibular process, MNP: medial nasal prominence, MX: maxillary process, NP: nasal pit, OL: odontogenic line, TV: telencephalic vesicle.
doi:10.1371/journal.pone.0069333.g005
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intracellular distribution in cells derived from wild-type and
affected embryos. Primary cultures of fibroblasts obtained from
E13.5 day old embryos were labeled with a-Pak1ip1 and a-
nucleolin antibodies. Our results confirmed an exclusive localiza-
tion of Pak1ip1 to the nucleolus, completely overlapping with
nucleolin immunoreactivity (figure 6). Interestingly, we did not see
any apparent differences in expression levels or subcellular
distribution of Pak1ip1 between wild-type and mutant cells,
suggesting that even though the mray allele disrupts the function of
Pak1ip1 it does not affect its localization in the cell.
A recent study by Yu et al. identified a regulatory role for
Pak1ip1 in cell growth and proliferation, via direct interaction with
the tumor protein 53 (Tp53)-murine double minute 2 (Mdm2)
loop upon detection of cellular stress [20]. Specifically, Pak1ip1
can either induce the Tp53-Mdm2 loop indirectly by activating
the Mdm2-binding ribosomal proteins Rpl5 and Rpl11 that act as
nucleolar stress signals or directly by binding and inhibiting the
ability of Mdm2 to ubiquitinate Tp53. Consequently, knockdown
of Pak1ip1 in cell culture has been shown to cause a decrease in
proliferation by inducing Tp53 dependent G1 cell cycle arrest. In
order to determine if the developmental defects seen in the mray/
mray mice are indeed caused by deregulation of the Tp53 pathway,
we performed a western blot analysis to compare Tp53 protein
levels between wild-type and mray/mray embryos at E10.5
(Figure 6). We found Tp53 levels to be significantly twofold
increased in the mutant further supporting the notion that the
ribosomal function of Pak1ip1 and the associated upregulation of
Tp53 in the homozygous mray mutants as being instrumental in
Figure 6. Pak1ip1 localizes to the nucleolus and its mutation increases Tp53 levels. Intracellular distribution of Pak1ip1 revealed through
immunofluorescence in cultured primary fibroblasts derived from wild-type (A–C) and homozygous mutant embryo (D–F). Fluorescent labeling for
Pak1ip1 (A, D), nucleolin (B, E), and merged colors with DAPI (C, F) show an exclusively nucleolar localization in wild-type (A–C) and mutant cells
(D–F) perfectly overlapping with the nucleolin signal. Scale bar is 10 mm. The western blot analysis in G performed on total lysate form E10.5
embryos reveals an upregulation of Tp53 in mray/mray mutants over wild-type littermates. The graph in H shows the results of the quantitative and
statistical analysis of relative band intensity compared to background for wild-type (black) and mray/mray (red) samples. Dots correspond to
individual data points, the thick lines show the mean, and the thin bars the standard error within the sample sets. A Student’s t-test was used to
assign significance to the data; a p-value ,0.05 was obtained from the analysis. In I, the results of a Mdm2 co-IP are shown, which was used to pull
Pak1ip1 protein from E13.5 embryo lysates. No differential signal intensity can be detected between wild-type and homozygous mutants for the
subsequent western analysis of Pak1ip1.
doi:10.1371/journal.pone.0069333.g006
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the manifestation of the craniofacial anomalies we see in this line
of mice.
To further uncover the mechanism by which mutant Pak1ip1
causes an upregulation in Tp53 levels, we examined its interaction
with Mdm2 using co-immunoprecipitation (Co-IP) analysis. Total
lysates from whole E13.5 embryos were immunoprecipitated using
a Mdm2 antibody and probed with a Pak1ip1 antibody, which did
not detect any differential binding between mutant (H122Y) and
wild-type Pak1ip1 protein to Mdm2 (figure 6, I). This is in support
of the notion that increased Tp53 levels in the mray/mray mutants
are caused by aberrant ribosome biogenesis and increased
nucleolar stress due to faulty or insufficient levels of translation.
In summary, we conclude that the mray allele does neither interfere
with the subcellular localization of Pak1ip1 nor with its ability to
interact with Mdm2 but apparently causes defects in ribosome
biogenesis that elicit a nucleolar stress response with associated
Tp53 upregulation.
Reduced proliferation rates of mray/mray cells can be
rescued by Tp53 inhibition
Since Tp53 protein levels are elevated in mutant embryos with
possibleG1 cell cycle arrest, we sought to examinewhether this leads
also to a reduction in the rate of cell proliferation within developing
craniofacial structures, as expected. We decided to count mitotic
cells within the palatal shelves at stage E13.5 prior to their elevation
since they present confined structures facilitating sampling. Consis-
tent with our hypothesis, the palatal shelves of homozygous mray
mutant embryos show a significant decrease in the ratio of
phosphorylated histone-H3 immunoreactive cells compared to the
palatal shelves of wild-type animals (figure 7, A–C). Since this loss of
proliferative activity in mutant cells is likely caused by higher Tp53
levels, we examined whether Tp53 inhibition has the capacity to
rescue the decreased proliferation rate. To that effect, we isolated
facial fibroblasts from E13.5 wild-type and mutant embryos and
cultured themwith orwithout theTp53-specific inhibitor pifithrin-a
(PFT-a). Proliferation rates were assessed by Click-iT EdU cell
proliferation assays utilizing incorporation and detection of the
modified nucleoside, EdU (5-ethynyl-29-deoxyuridine) in dividing
cells. Comparing the ratio of dividing over non-dividing cells within
a two-hour interval, we identified a substantial reduction in mitotic
cells in the mutant (figure 7, D–H). Administration of 2.2 mg/ml of
PFT-a in the culture media of wild-type and mutant cells lead to a
significant increase in the proliferation rate of mutant cells but had
no significant effect onwild-type cells compared to controls.Overall,
inhibition of Tp53 using PFT-a increased proliferation levels of
mray/mray cells to levels comparable to their wild-type counterparts.
PAK1IP1 association and sequencing studies
Next we examined the possibility that PAK1IP1 (6p24.2) may be
a human disease gene as was suggested by studies that mapped
translocation breaking points associated with cleft lip and palate to
human chromosome 6p24.1 [7,8]. PAK1IP1 maps at a distance of
less than 1 to these breaking points hinting at a possible role as
disease gene or contributing factor to the manifestation of the
craniofacial pathology in these patients (figure 8). To examine this
possibility, we conducted sequencing and association studies on a
set of samples obtained from 271 Filipino non-syndromic cleft lip
and palate patients and their respective parents. First, we
established a Hapmap haplotype block for the PAK1IP1 region
looking for SNPs with a minor allele frequency (MAF) of at least
0.2 in the Chinese (CHB) and Japanese (JPT) populations.
PAK1IP1 spans 14.78 kb and does not contain SNPs with a
MAF higher than 0.15 for these populations. We then proceeded
to expand the search for informative SNPs to 100 kb around the
gene and selected 3 SNPs to genotype: rs4712827, rs521417, and
rs494723, marked with boxes in the plot in figure 8. Our
association analysis showed that marker rs494723 was significantly
associated with CL/P cases (p = 0.01; tables 1 and 2). A genome-
wide association study reported a SNP about 1 Mb from PAK1IP1
that reached a p value of 5.50 E-05 (rs760788) [3]. In addition, we
conducted a case-control analysis in 259 Polish cases and 493
unrelated Polish controls. Results are listed in tables 3 and 4;
similarly to our Filipino trio association results only rs494723
showed borderline significance (p = 0.0437).
We proceeded to sequence the 10 exons of PAK1P1 in samples
obtained from 271 Filipino non-syndromic cleft lip and palate
patients. We identified 3 not previously reported noncoding
variants, an A/C change at chr6:10,695,513 was found in 4
patients while chr6:10,707,487 (A/T) and chr6:10,707,787 (A/G)
was only found in one patient each. These variants are considered
new since they are not present in public databases, which include
over 7,000 individually sequenced whole exomes [28,29]. How-
ever, no unambiguously deleterious mutations were identified with
this approach.
Discussion
The Centers for Disease Control estimate that orofacial clefts
with an average worldwide rate of 1 to 700 are the most common
birth defects. Consequently, the search for genetic factors causing
these defects is a high priority in addressing diagnostic, preventive,
and therapeutic needs for orofacial clefts [30]. In a forward genetic
screen in mice, we identified a mutation in the Pak1ip1 gene that
causes a median cleft with cleft palate in homozygous mutants.
These animals present us with the first described mutant allele of
the Pak1ip1 gene in mice. Pak1ip1 is a molecule of approximately
50 kDa almost entirely comprised of five WD40 repeats, which
have been characterized as sites of protein-protein interaction to
which proteins can bind either stably or reversibly to form larger
assemblies. The structural characteristics of Pak1ip1 indicate that
it has a multitude of distinct molecular interactions underlining its
complex role in cellular function. Originally, it was described as a
negative regulator of the serine-threonine kinase Pak1 (P21-
activated kinase) thus mediating processes of gene expression,
cytoskeletal actin and tubulin assembly, cell cycle control, and
apoptosis [15,16]. Subsequent studies have shown that next to its
presumed function in cytoskeletal regulation, Pak1ip1 also
localizes to the nucleolus where it is involved in ribosome
biogenesis, specifically the assembly of the 60S ribosomal subunit
[19]. As a preribosomal factor, Pak1ip1 facilitates ribosomal RNA
processing and plays a regulatory role in cell growth and
proliferation, apparently through direct interaction with the tumor
protein 53 (Tp53)-murine double minute 2 (Mdm2) loop upon
cellular stress [20]. Its function suggests impairment in ribosome
biogenesis as the underlying cause of the observed craniofacial
defects in Pak1ip1mray/mray mutants, which is also supported by our
findings. Specifically, we identified both an exclusive localization
of Pak1ip1 to the nucleolus and an upregulation of Tp53 levels in
homozygous mray embryos during the early formation of
craniofacial structures (figure 6), consistent with the notion that
cellular stress causes Tp53-dependent G1 cell-cycle arrest associ-
ated with the reduced outgrowth of midfacial structures. Further-
more, we found the rate of proliferation within the developing
palatal shelves of the mutants to be significantly decreased and
pharmacological inhibition of Tp53 with pifithrin-a in primary
facial fibroblasts was able to rescue this proliferative deficit in vitro.
Interestingly, the mray allele neither interferes with the nucleolar
localization of mutant Pak1ip1H122Y, which is expected since its
A Mutation in Paklip1 Causes Orofacial Clefting
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nuclear and nucleolar localization signals were previously mapped
to the C-terminus of the protein (corresponding to amino acid
residues 366–382 in mouse) [20], nor with its affinity to the Tp53
regulator Mdm2. Yu et al. proposed two mechanisms by which
Pakip1 can elicit an upregulation of Tp53 levels resulting in cell
cycle arrest. First, by overexpression and direct inhibition of
Mdm2 inhibiting its ability to ubiquitinate and degrade Tp53 and
second, indirectly after knockdown, by increasing the concentra-
tion of free ribosomal proteins L5 and L11, which also bind to and
inhibit Mdm2. In Mdm2-Pak1ip1 co-immunoprecipitation exper-
Figure 7. Proliferation deficits in mray/mray embryos can be rescued in vitro by Tp53 inhibition. Coronal sections through the palatal
shelves of wild-type (A) and mray/mray mutant embryos (B) at E13.5 demonstrate a severe reduction in mitotic cells in the mutant as detected by
pHH3 immunofluorescence. The quantification of the results is shown in C as a ratio of pHH3+ to DAPI+ cells. * represents a p-value ,0.02. EdU cell
proliferation assay on cultured primary facial fibroblasts from wild-type (D) and manta-ray homozygous mutants (F) reveals a reduced rate of
proliferation in mutant cells. This deficit can be averted by treatment with the Tp53 inhibitor pifithrin-a, which significantly increased cell proliferation
in mutant cells, but had no apparent effect on wild-type cells as shown in the quantification in H given as a ratio of EDU+ to DAPI+ cells. A total of five
independent fields were analyzed between three slides for the experiment. EDU+: DAPI+ ratios for individual fields are represented by the circles (WT
control), squares (WT + PFTa), triangles (MUT control) and upside down triangles (MUT + PFTa). Middle bar represents the mean value, with top and
bottom bars representing standard error of the mean. * represents a p-value ,0.02. EDU+: DAPI+ ratio was not significantly different between WT
control, WT + PFTa, and MUT + PFTa groups. MUT: mutant, PS: palatal shelves, WT: wild-type. Scale bars are 30 mm.
doi:10.1371/journal.pone.0069333.g007
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iments using either wild-type or mutant lysates, we did not detect
any differences between genotypes strongly suggesting the mray
allele as a loss-of-function mutation disabling the proper partic-
ipation of the mutant protein in ribosome biogenesis. We also
examined a possible local, midfacial deregulation of signaling
molecules important for midfacial outgrowth such as Fgf8, Fgf17,
and Shh, but detected only mild changes in the craniofacial
expression of these genes. It is very unlikely that low-level changes
Figure 8. Mouse/Human synteny and Haploview output showing linkage disequilibrium relationships of the analyzed SNPs.
Approximately 1 Mb of syntenic aspects of mouse chromosome 13 and human chromosome 6 containing the Pak1ip1/PAK1IP1 genes are shown in
National Center for Biotechnology Information Sequence Viewer 2.25 generated images in A. Positions and exon/intron structure of genes are
indicated as green lines. In addition, the translocation breakpoint closest to PAK1IP1 reported in [8] is indicated through an arrowhead. In B the
Haploview generated LD block structure encompassing 100 kb around PAK1IP1 for the Han Chinese and Japanese populations combined is
presented. The upper part shows the genomic region of the PAK1IP1 gene and boxed the SNPs used in our association analysis and their physical
position relative to PAK1IP1. Marker to marker D9 statistics are shown below with linkage disequilibrium (LD) blocks defined as solid spine of LD with a
D9.0.8. Cells with no value indicate D9= 1.0. Color intensity indicate strength of association, the darker the cell the greater the LD between individual
SNPs. The haplotype block is outlined.
doi:10.1371/journal.pone.0069333.g008
Table 1. Family association results.
Marker Allele afreq Fam# Z P
rs521417 C 0.748 105 1.635 0.102081
rs4712827 T 0.627 151 1.082 0.279393
rs494723 T 0.695 108 2.562 0.010406
Results of the family-based association test on Filipino trios consisting of a
nonsyndromic CL/P patient and both parents.
doi:10.1371/journal.pone.0069333.t001
Table 2. Results of the haplotype analysis of the selected
SNPs in the family-based association study.
Haplotype Frequency Fam# Z P
CTT 0.367 92.4 2.028 0.042519
CCC 0.235 80 21.912 0.055844
ATT 0.166 67.4 20.755 0.450089
CCT 0.082 41.9 1.187 0.235181
ACC 0.07 32.3 20.939 0.347959
CTC 0.047 25.1 20.726 0.467776
ACT 0.019 9.6 N/A N/A
ATC 0.014 7.8 N/A N/A
Results of the haplotype analysis of markers rs521417, rs4712827, and rs494723
for the Filipino trios. afreq: allele frequency, Fam#: number of informative
families, Z: z-score, P: p-value.
doi:10.1371/journal.pone.0069333.t002
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in the midfacial expression of these genes causes the midline
defects seen in homozygous mray mutants, particularly in light of a
recent study by Griffin et al., which found that a loss of
approximately 80% of Fgf8 expression in Fgf8null/neo mice is
required to cause a midfacial cleft of comparable extent to the cleft
in the Pak1ip1mray/mray mutants [31]. Overall, our findings are
consistent with the hypothesis that aberrant ribosome biogenesis
associated with cell cycle arrest caused by increased Tp53 activity
is the major mechanism underlying the craniofacial hypoplasia
displayed by homozygous mray mutants.
Pathological changes of a similar nature to the mray/mray
phenotype can be seen in human ribosomopathies such as
Diamond-Blackfan anemia (DBA) or Treacher Collins syndrome
(TCS), which are associated with craniofacial malformations
including cleft palate [32,33]. Further, in a recent study in Tail
short (Ts) mice, which are characterized by a partially penetrant
midfacial cleft of very similar appearance to the phenotype seen in
homozygous mray mutants, causative mutations were identified in
the gene encoding the ribosomal protein L38 (Rpl38) [34].
Interestingly, in mice carrying mutations in the Tcof gene, a
successful rescue of the mutant craniofacial phenotype was
achieved by both pharmacological and genetic inhibition of
Tp53. Taken together with the results we present here, we suspect
that in future studies a similar rescue may be possible for the mray/
mray mutant mice too.
While orofacial clefts are very common birth defects, median
clefts such as the one displayed by the Pak1ip1mray/mray animals are
extremely rare.Median clefts arise from the failure of the frontonasal
processes to fuse along themidline during development. To this date
no causative mutation for isolated midline clefting in humans has
been identified but midline clefts are commonly seen in holopro-
sencephaly syndromes for which several genes have been identified.
In addition, a few genetically defined mouse models exist. These
include compoundmutants of the (Alx42/2/Cart1+/2) [35], retinoic
acid receptors anda and c doublemutants (Rara2/2/Rarc2/2) [36],
and platelet-derived growth factor receptor mutants (Pdgfraph/ph,
Pdgfra2/2) [37,38]. In Tail short (Ts) mice, which show with partial
penetrance a midfacial cleft, causative mutations were identified in
the gene encoding the ribosomal protein L38 (Rpl38) [34]. This
finding may point to a more general role for ribosome biogenesis
defects and associated deficits in protein biosynthesis as an
underlying cause for median clefts.
The possible role for PAK1IP1 (6p24.2) in human disease was
suggested by studies mapping translocation breaking points
associated with cleft lip and palate in affected individuals to
human chromosome 6p24.1 [7,8]. PAK1IP1 maps between 0.5
and 1 Mb of these breaking points making it a possible candidate
or contributing factor to the manifestation of the disease
phenotype in these patients. To examine this possibility, we
conducted sequencing and association studies. While our results
did not provide clear evidence associating PAK1P1 with orofacial
clefts, some association was seen for the nearby marker rs494723
and for a haplotype (Table 1).
Several factors may explain the fact that we did not find a
mutation within the coding sequences of PAK1IP1. First, as for the
mray allele, prenatal lethality of human carriers may eliminate them
from the general and our sample population. Second, none of the
samples tested was derived from a patient with the specific
pathological features seen in the Pak1ip1mray/mray mutants, a median
orofacial cleft with cleft palate. Third, we only sequenced the
PAK1IP1 coding region in the Filipino samples since Schultz et al.
have demonstrated linkage to a neighboring region (6p23) in this
population [11]; however,it remains possible that etiologic variants
are harbored in non-coding regulatory elements. Future studies can
utilize different sample sets, particularly sets that include samples
from patients with median clefts and relevant neuronal defects as
well as populations of different genetic background. In summary, our
findings point towards an important role for Pak1ip1 as a
developmental regulator, particularly in the formation of the cranial
skeleton, but require further study to understand its disease relevance
in the manifestation of congenital craniofacial malformations.
Materials and Methods
Ethics statement
The study was approved by the University of Iowa Institutional
Review Board (IRB) in the United States under IRB-01 ID
Table 3. Case-control association results.
Marker Allelesa MAFb
Genotypes
casesc
Genotypes
controlsc
Pgenotypic
value
Pallelic
value
Ptrend
value
ORdominant (95% CI)
d;
p-value
ORrecessive
(95% CI)e; p-
value
rs521417 a/C 0.38 111/112/36 182/244/67 0.2287 0.2835 0.2808 0.780 (0.54 – 1.060);
0.1125
1.026 (0.664 –
1.588); 0.9067
rs4712827 c/T 0.46 78/118/63 143/247/103 0.4277 0.6679 0.6716 0.948 (0.682 – 1.318);
0.7509
1.217 (0.851 –
1.740); 0.2809
rs494723 c/T 0.29 151/93/15 249/206/38 0.1165 0.0437 0.0426 0.730 (0.53920.989);
0.0418
0.736 (0.397 –
1.365); 0.3292
Results of the Polish case-control association analysis. aUppercase denotes the more frequent allele in the control samples, bMAF, minor allele frequency calculated from
the control samples, cThe order of genotypes: DD/Dd/dd (d is the minor allele), dDominant model: dd + Dd vs DD (d is the minor allele), eRecessive model: dd vs Dd +
DD (d is the minor allele).
doi:10.1371/journal.pone.0069333.t003
Table 4. Results of the haplotype analysis of the selected
SNPs in the case-control study.
SNP Combination X2 Global p-value
2-marker window
rs4712827_rs521417 1.613 0.656
rs521417_rs494723 3.967 0.265
3-marker window
rs4712827_rs521417_rs494723 9.404 0.152
Results of the haplotype analysis of markers rs521417, rs4712827, rs494723 in
the Polish unrelated non-syndromic CL/P cases. Empirical 5% quantile of the
best p-value: 0.009972 (1,000 permutations).
doi:10.1371/journal.pone.0069333.t004
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#199804080; Title: Studies of Genes Involved in Human Head,
Face and Eye Disorders. Informed written consent was obtained
from all participating individuals or legal caretakers and the data
were analyzed anonymously. Filipino cases were recruited through
ongoing follow-ups of families originally identified during Oper-
ation Smile medical missions and all practices were approved by
the Internal Review Board of the Corazon Locsin Montelibano
Memorial Regional Hospital [39]. Polish case eligibility was
ascertained by clinicians using detailed diagnostic information
from medical records and following guidelines established by the
Medical Ethics Committee of the Supreme Medical Council of the
Polish Chamber of Physicians and Dentists (PCHPD). The study
was approved by the ethical committee of the Poznan University
of Medical Sciences. Written and oral consent was obtained from
all participants. Mice were housed in specific-pathogen-free
facilities approved by the Association for Assessment and
Accreditation of Laboratory Animal Care International (AALAC).
All animals were handled in accordance with protocols approved
by the University of California at Davis Institutional Animal Care
and Use Committee.
Animal husbandry and genotyping
The colony of animals carrying the Pak1ip1mray allele (induced
on C57BL/6J background) is maintained by crossing male carriers
with FVB/NJ females. This mode of outcross is currently in the
ninth generation without any changes in penetrance or variability
of the mutant phenotype. All embryos presented in the phenotypic
analysis of this study were produced from carriers crossed for at
least four generations onto an FVB/NJ background. Routine
genotyping was performed by amplifying microsatellites
D13Mit63 and D13Mit177.
Positional mapping and candidate gene sequencing
The mray line was recovered in a genetic screen for recessive
mutations disrupting forebrain development [23]. Positional
mapping was performed using simple-sequence length polymor-
phic markers available from the Whitehead Institute for Biomed-
ical Research, MIT. Initial linkage was established after a genome-
wide scan using 82 simple sequence repeat markers on 12 DNA
samples from both carriers and mutant embryos. For high-
resolution meiotic mapping, we scored separate crosses resulting in
over 1572 generated meioses (carriers and embryos counted).
Using this approach, we located the mray mutation to an interval
on chromosome 13 between markers D13Mit177 (38.975 Mb)
and D13Mit63 (42.709 Mb) in the NCBI mouse assembly (Build
37.2, current assembly). The identified genetic interval contained
22 protein-coding genes of which all exons were amplified and
sequenced from genomic DNA samples. For every set of primers,
we used samples of the two parental strains (C57BL/6J and FVB/
NJ) and two samples of affected mutants. All primer sequences are
available upon request. Sequence comparisons were carried out
using Mutation SurveyorH DNA variant analysis software (Soft-
Genetics, LLC, State College, PA) and BLAST (National Center
for Biotechnology Information). Sequences of insufficient quality
or read length were dismissed from any comparisons and repeated
with revised primer sets. To further confirm that the mutation in
Pak1ip1 is causative, we genotyped a total of 116 phenotypically
mutant embryos (232 meioses) of stages E11.5 to E14.5, which are
easy to score. For genotype analysis, we used a restriction length
polymorphism created by the manta-ray allele (additional HindIII
site) and found that all affected embryos carried the mutant variant
in a homozygous state.
Embryo imaging and histology
Embryos of all developmental stages analyzed, were recovered
after timed pregnancies and fixed by immersion in 4% parafor-
maldehyde in phosphate buffered saline (PBS). For some whole-
mount imaging, embryos were stained with ethydium bromide at
10 mg/ml in PBS for several hours, briefly washed with several
exchanges of PBS, and photographed under fluorescent illumina-
tion. Nissl stained (cresyl violet) or hematoxylin and eosin stained
histological sections of 10 mm thickness were prepared from
paraffin-embedded tissue using standard procedures. All RNA in
situ hybridization on whole-mount embryos and sections was
performed using standard procedures as previously described [40].
For each marker and developmental stage shown, we analyzed per
experiment at least three embryos of each genotype (wild-type,
heterozygote, mutant) and carried out every experiment at least
twice. The Pak1ip1 riboprobe was transcribed from a 1.1 kb cDNA
fragment containing the entire coding region of the gene (base
pairs 321–1469 in NM_026550). Plasmids to transcribe riboprobes
for Fgf8, Fgf17, and Shh were kindly provided by Dr. John L.R.
Rubenstein.
Immunocytochemistry and immunohistochemistry
Primary fibroblasts were isolated from the facial mesenchyme of
E13.5 embryos. Upon removal from the uterus, embryos were
placed into ice-cold HBSS where the facial mesenchymal tissue
was then isolated. The tissue was treated with DNase and trypsin-
EDTA for 13 minutes at 37uC, the dissociated cells resuspended in
Dulbecco’s Modified Eagle Medium (DMEM), and plated on
poly-D-lysine coated Lab-Tek chamber slides (Nunc, Rochester,
NY). After incubation for at least 24 h cells were fixed in ice cold
4% PFA in PBS (pH 7.4) for 15 minutes prior to being
permeabilized using PBS +0.25% Triton X-100. After blocking
in 1% BSA (in 16 PBS +0.1% Tween-20) for one hour the cells
were incubated in primary antibodies for Pak1ip1 (1:400; Orbigen,
San Diego, CA) and nucleolin (1:1000; AbCam, Cambridge, MA).
Cells were washed with PBS and incubated with the appropriate
secondary antibodies (CY3, 1:250 and 488M 1:1000) in 1% BSA
in PBS (Alexa Fluor, Invitrogen, Carlsbad, CA). Prior to the final
PBS rinse, cells were counterstained with the fluorescent nucleic
acid stain 4’,6-diamidino-2-phenylindole (DAPI, Invitrogen,
Carlsbad, CA), coverslipped, and imaged using a Nikon scanning
confocal laser microscope with the associated proprietary software
(Nikon Instruments, Tokyo). Phospho-histone H3 immunofluores-
cent analysis was carried out on 14 mounted sections cut from
tissue fixed in 4% paraformaldehyde/PBS and cryoprotectively
frozen in 30% sucrose using an a-pHH3 antibody (1:400, Abcam,
Cambridge, MA). Same buffers and incubations were used as
described above.
Western analysis
25 mg of protein lysates obtained from whole E10.5 embryos
were run on a Nu-Page 4–12% Bis-Tris gels (Invitrogen, Carlsbad,
CA). Proteins were transferred to nitrocellulose membranes and
blocked in Odyssey blocking buffer (Li-Cor Biosciences, Lincoln,
NE). Membranes were incubated with Tp53 primary antibody
(1:,000; Cell Signaling Technology, Boston, MA) diluted in
Odyssey blocking buffer +0.1% Tween-20, overnight at 4uC.
After washing, we incubated with Li-Cor IR secondary antibody
(1:15,000; Li-Cor Biosciences, Lincoln, NE) in Odyssey blocking
buffer +0.1% Tween-20, washed, and imaged on the Li-Cor
Odyssey IR scanner. The process was repeated with b-actin as
loading control (Novus Biologicals, Littleton, CO). Protein sizes
were assigned using the Li-Cor infrared two-color protein marker.
Signal intensity relative to background was determined using Li-
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Cor Image Studio version 2.0 software and Prism version 6
software was used to calculate standard error and perform a t-test
in order to assign statistical significance to the results (GraphPad
Software, La Jolla, CA).
Co-immunoprecipitation analysis
All experiments were conducted in triplicate using components of
the Immunoprecipitation Kit – Dynabeads Protein G from
Invitrogen (Carlsbad, CA). 1 mg of whole embryo (E13.5) protein
lysate from wild-type and mray/mray animals was incubated with
10 mg of Mdm2 antibody (Abcam, Cambridge, MA) and 200 ml of
antibody binding buffer overnight on a rocker at 4uC. Subsequently,
50 ml of protein-G dynabeads were added to the mixture, and
incubated on a rocker at 4uC for 2.5 hours. Following this step, the
bead-antibody-protein complex was washed thrice with 200 ml of
wash buffer before being suspended in 30 ml of a 70% 46LDS and
30% 106reducing agent solution. The samples were then boiled for
10 minutes at 70uC prior to being loaded (15 ul) onto a 4–12% bis-
tris gel (Invitrogen). Western analysis was carried out as described
above exposing the membrane to 1 mg/ml of Pak1ip1 antibody
(Orbigen, San Diego, CA) for 12 hours at 4uC.
EdU proliferation assay
Primary facial fibroblast cells from wild-type and homozygous
manta-ray mutants were cultured in DMEM growth media on 4-
chambered culture slides (Nunc, Rochester, NY) for 24 hours with
or without 2.2 mg/ml of the Tp53 inhibitor pifithrin-a (Sigma) and
then exposed to 10 mM 5-ethynyl-2’-deoxyuridine (EdU, Invitro-
gen, Carlsbad, CA) for two hours at 37uC. Subsequently, cells
were fixed in 4% paraformaldehyde in PBS prior to click
chemistry development of EdU and DAPI staining. For the
quantification of EDU+ and DAPI+ cells, a total of five randomly
selected independent fields (6006600 mm) between three slides for
each experimental group were analyzed. Each field contained
approximately 100 cells. Statistical significance was assigned using
a two-tailed Student’s t-test with Prism version 6 software
(GraphPad Software, La Jolla, CA).
Human subjects
Two hundred and fifty nine NSCL/P patients (228 cases with
cleft lip and palate and 31 cases with cleft lip only) were identified
from the Department of Pediatrics and Pediatric Surgery at the
Institute of Mother and Child in Warsaw as well as from the
University Clinic of the Medical Academy in Wroclaw and the
Department of Plastic Surgery Specialist Medical Center in
Polanica Zdroj. The control group was composed of 493 healthy
individuals with no family history of clefts or other major
congenital anomalies. Controls were matched with the NSCL/P
patients for age, sex and the place of residence. Peripheral blood
samples were obtained from selected individuals in both popula-
tions and DNA was extracted.
Association study
Single nucleotide polymorphisms (SNPs) were selected using the
Hapmap Project and Haploview tagged SNPs for the Chinese and
Japanese population, restricting minor allele frequencies to 0.2 and
selecting enough SNPs to provide at least 80% genetic coverage of
haplotype blocks [41]. Selected SNPs (Table 1) were genotyped by
allelic discrimination using Taqman assays (Applied Biosystems,
Foster City, CA, USA) in 307 Filipino trios consisting of a
nonsyndromic CL/P patient and both parents. Association was
assessed using Familiy Based Association Test (FBAT) [42].
Case-control Study
The same SNPs as in the association study were genotyped by
high-resolution melting curve analysis (HRM) on the LightCycler
480 system (Roche Diagnostics, Mannheim, Germany) in a set of
259 nonsyndromic CL/P cases and 493 unaffected controls. The
differences in allele and genotype frequencies between case and
control mothers were determined using Chi-square test. SNPs
were tested for association with NSCL/P using the Cochran-
Armitage trend test. The strength of association was estimated by
Odds Ratio (OR) and a corresponding 95% confidence interval
(95%CI). Both recessive and dominant inheritance models were
analysed. A p-value , 0.05 was considered statistically significant.
Haplotype based association analysis was performed using the
UNPHASED 3.1.5 program with the following analysis options:
all window sizes, full model and uncertain haplotype option.
Haplotypes with a frequency below 0.01 were set to zero [43].
Significant p-values were corrected using the 1000-fold permuta-
tion test.
Direct sequencing
The PAK1IP1 coding region was sequenced in 273 Filipino
nonsyndromic CL/P patients. Primers were designed using
primer3 and are available upon request [44]. Templates for
sequencing were generated by PCR in an Applied Biosystems
Gene Amp PCR System 9700, as described in Mansilla et al. [45].
Sequencing reactions were resolved on an ABI Prism 3700
analyzer and analyzed by Polyphred 4.0 and Consed.
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